Brian Schulte, MD

Title(s)Assistant Professor, Medicine
SchoolSchool of Medicine
Address550 16th Street, #6558
San Francisco CA 94158
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    Duke UniversityBSE05/2009Biomedical Engineering
    Medical College of WisconsinMD05/2015
    University of Colorado06/2018Internal Medicine
    Northwestern University, Fellowship06/2021Hematology/Oncology
    University of California, San Francisco, CA10/2021Diversity, Equity, and Inclusion Champion Training
    Collapse Awards and Honors
    2014Alpha Omega Alpha
    Northwestern University2019  - 2020Chief Fellow Hematology/Oncology

    Collapse Overview 
    Collapse Overview
    Dr. Brian Schulte is a hematologist-oncologist who cares for patients with sarcomas, rare cancers that develop in connective tissues (such as bone, muscle or cartilage) and can affect people of all ages. Working as part of a multidisciplinary team, he strives to ensure patients receive the best possible comprehensive care. In research, Dr. Schulte studies novel medications, alone and in combination, to treat sarcoma.
    After earning a bachelor's degree in engineering at Duke University, Dr. Schulte earned his medical degree at the Medical College of Wisconsin and completed a residency in internal medicine at the University of Colorado Anschutz Medical Campus. He completed a fellowship in hematology-oncology at Northwestern University Feinberg School of Medicine, where he served as chief fellow.

    Collapse ORNG Applications 
    Collapse Clinical Trials

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Considerations for Prompting Large Language Models. JAMA Oncol. 2024 Feb 15. Schulte B. PMID: 38358765.
      View in: PubMed   Mentions:    Fields:    
    2. PD-1 Inhibition in metastatic high tumour mutational burden (TMB) leiomyosarcoma with clinicopathological correlates. BMJ Case Rep. 2023 Nov 17; 16(11). Pandita D, Dave M, Schulte B. PMID: 37977843; PMCID: PMC10660649.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    3. Cardiac Safety of Pegylated Liposomal Doxorubicin After Conventional Doxorubicin Exposure in Patients With Sarcoma and Breast Cancer. Cureus. 2023 Sep; 15(9):e44837. Alhaja M, Chen S, Chin AC, Schulte B, Legasto CS. PMID: 37809186; PMCID: PMC10559758.
      View in: PubMed   Mentions:
    4. Capacity of ChatGPT to Identify Guideline-Based Treatments for Advanced Solid Tumors. Cureus. 2023 Apr; 15(4):e37938. Schulte B. PMID: 37220429; PMCID: PMC10200252.
      View in: PubMed   Mentions: 9  
    5. Targeted therapies for the treatment of soft tissue sarcoma. Front Oncol. 2023; 13:1122508. Fuchs JW, Schulte BC, Fuchs JR, Agulnik M. PMID: 36969064; PMCID: PMC10034045.
      View in: PubMed   Mentions: 3  
    6. Emerging targeted and cellular therapies in the treatment of advanced and metastatic synovial sarcoma. Front Oncol. 2023; 13:1123464. Fuchs JR, Schulte BC, Fuchs JW, Agulnik M. PMID: 36761952; PMCID: PMC9905840.
      View in: PubMed   Mentions: 2  
    7. B7-H3 Specific CAR T Cells for the Naturally Occurring, Spontaneous Canine Sarcoma Model. Mol Cancer Ther. 2022 06 01; 21(6):999-1009. Zhang S, Black RG, Kohli K, Hayes BJ, Miller C, Koehne A, Schroeder BA, Abrams K, Schulte BC, Alexiev BA, Heimberger AB, Zhang A, Jing W, Ng JCK, Shinglot H, Seguin B, Salter AI, Riddell SR, Jensen MC, Gottschalk S, Moore PF, Torok-Storb B, Pollack SM. PMID: 35405743.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansAnimalsCells
    8. CD4+ T cell and M2 macrophage infiltration predict dedifferentiated liposarcoma patient outcomes. J Immunother Cancer. 2021 08; 9(8). Schroeder BA, LaFranzo NA, LaFleur BJ, Gittelman RM, Vignali M, Zhang S, Flanagan KC, Rytlewski J, Riolobos L, Schulte BC, Kim TS, Chen E, Smythe KS, Wagner MJ, Mantilla JG, Campbell JS, Pierce RH, Jones RL, Cranmer LD, Pollack SM. PMID: 34465597; PMCID: PMC8413967.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansCells
    9. An open-label single-arm phase II study of regorafenib for the treatment of angiosarcoma. Eur J Cancer. 2021 09; 154:201-208. Agulnik M, Schulte B, Robinson S, Hirbe AC, Kozak K, Chawla SP, Attia S, Rademaker A, Zhang H, Abbinanti S, Cehic R, Monga V, Milhem M, Okuno S, Van Tine BA. PMID: 34284255.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCTClinical Trials
    10. Glandular metastases from renal cell carcinoma show poor clinical responses to immune checkpoint inhibition but durable responses to angiogenesis inhibitors. BMJ Case Rep. 2021 Jun 22; 14(6). Principe DR, Schulte BC, Kamath SD, Munshi HG. PMID: 34158333; PMCID: PMC8220521.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    11. Phase II study of pazopanib with oral topotecan in patients with metastatic and non-resectable soft tissue and bone sarcomas. Br J Cancer. 2021 08; 125(4):528-533. Schulte B, Mohindra N, Milhem M, Attia S, Robinson S, Monga V, Hirbe AC, Oppelt P, Charlson J, Helenowski I, Abbinanti S, Cehic R, Okuno S, Van Tine BA, Agulnik M. PMID: 34050255; PMCID: PMC8368095.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansCTClinical Trials
    12. Metastatic Myxofibrosarcoma with Durable Response to Temozolomide Followed by Atezolizumab: A Case Report. Oncologist. 2021 07; 26(7):549-553. Lambden JP, Kelsten MF, Schulte BC, Abbinanti S, Hayes JP, Villaflor V, Agulnik M. PMID: 33594725; PMCID: PMC8265341.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    13. Sorting Through the Maze of Treatment Options for Metastatic Castration-Sensitive Prostate Cancer. Am Soc Clin Oncol Educ Book. 2020 Mar; 40:1-10. Schulte B, Morgans AK, Shore ND, Pezaro C. PMID: 32182139.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    14. Characterization of clinical grade CD19 chimeric antigen receptor T cells produced using automated CliniMACS Prodigy system. Drug Des Devel Ther. 2018; 12:3343-3356. Zhang W, Jordan KR, Schulte B, Purev E. PMID: 30323566; PMCID: PMC6181073.
      View in: PubMed   Mentions: 25     Fields:    Translation:HumansCells
    15. Azelaic Acid: Evidence-based Update on Mechanism of Action and Clinical Application. J Drugs Dermatol. 2015 Sep; 14(9):964-8. Schulte BC, Wu W, Rosen T. PMID: 26355614.
      View in: PubMed   Mentions: 20     Fields:    Translation:Humans
    16. Depletion of M2-like tumor-associated macrophages delays cutaneous T-cell lymphoma development in vivo. J Invest Dermatol. 2014 Nov; 134(11):2814-2822. Wu X, Schulte BC, Zhou Y, Haribhai D, Mackinnon AC, Plaza JA, Williams CB, Hwang ST. PMID: 24780929.
      View in: PubMed   Mentions: 47     Fields:    Translation:HumansAnimalsCells
    Brian's Networks
    Concepts (92)
    Derived automatically from this person's publications.
    Co-Authors (4)
    People in Profiles who have published with this person.
    Similar People (60)
    People who share similar concepts with this person.
    Same Department
    Search Department